Asset profile
PRT3789
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT05639751 · Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05639751: This was an open-label, non-randomized dose-finding study with no control group, designed to establish a tolerable dose rather than to test efficacy; results have not yet been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.